PTC THERAPEUTICS, INC. 8-K

What Happened

• PTC Therapeutics, Inc. announced on April 28, 2026 that it reported positive topline results from the 24‑month interim analysis of the PIVOT‑HD long‑term extension study of votoplam. The company filed a Regulation FD disclosure (Form 8‑K) and scheduled a virtual presentation of the results for April 28, 2026 at 4:30 p.m. Eastern, to be webcast live on the Investors → Events and Presentations page of its website. The related press release and slide presentation are furnished as Exhibits 99.1 and 99.2 to the 8‑K.

Key Details

• Filing date: April 28, 2026 (Form 8‑K; Item 7.01 Regulation FD Disclosure and Item 9.01 exhibits).
• Announcement: Positive topline results from the 24‑month interim analysis of the PIVOT‑HD long‑term extension study for votoplam.
• Investor event: Virtual presentation/webcast on April 28, 2026 at 4:30 p.m. Eastern.
• Exhibits: Press release (Exhibit 99.1) and corporate presentation/slides (Exhibit 99.2) were furnished with the filing; Form signed by CFO Pierre Gravier.

Why It Matters

• Positive 24‑month topline data is a material clinical update that advances votoplam’s development program and provides investors with new information about the drug’s longer‑term performance. The webcast and published slides give investors access to the company’s reported findings and any management commentary. Investors should review the press release and presentation (Exhibits 99.1/99.2) for details on outcomes, endpoints and next steps, as the 8‑K itself provides the disclosure but not the full study data.